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Original Article
Abstract
Purpose: This study was done to evaluate response, compliance and survival of weekly low dose cisplatin (20 mg/m2) and gem-
citabine (125 mg/m2) concurrently with pelvic radiation as primary treatment of stage IIB-IIIB cervical cancer.Methods: External
radiation consisted of 50 Gy/25 fractions using 6-10 MV photon followed by 600 cGy boost to parametrium if it was still felt
thickened. Then, intracavitary radiotherapy to deliver 60 Gy at point A. Chemotherapy consisted of gemcitabine at a dose of 125
mg /m2 was given by i.v infusion over 30 minutes immediately after cisplatin 20 mg /m2 weekly for 5 weeks during EBRT. Forty–
five eligible patients received the treatment protocol. Results: Toxicity was tolerable and manageable. No grade 4 toxicity while
grade 3 was recorded in hematologic one only. In order of frequency; diarrhea, nausea and vomiting, and anemia (50%, 40%,
35.5%) were most common adverse events. Overall clinical response rate was 93.4% with pathological complete response of
62.2%. After median follow-up of 20 months, 2-year survival and progression-free survival rates were 90.5% and 81% respec-
tively. Conclusion: Weekly combination of low- dose cisplatin and gemcitabine given concurrently with pelvic radiotherapy in
primary treatment of locally advanced cervical cancer resulted in a high response rate with a good compliance. Further explora-
tion is needed for the use of this approach prior to incorporating it into routine clinical care through phase III clinical trial.
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Introduction
Uterine cervical cancer is the second most common female
malignancy in the world.1 However, the incidence of it has
decreased markedly in recent decades following the intro-
duction of screening programs.2 Usually cervical carcinoma
presents as a locally advanced disease with parametrial infil-
tration in about half of the women especially in developing
countries due to lack of early detection programs. Co-chrane
meta-analysis in nearly 5000 patients strongly suggested that
chemo-radiotherapy leads to greater disease-free and overall
survival rates and better local control than with radical radi-
otherapy alone in locally advanced cervical cancer.3 Induc-
tion chemo-radiotherapy can be followed by surgical con-
solidation. This approach has a sound theoretical bases as
surgery may eliminate residual disease which otherwise could
be resistant to chemo-radiation.
Gemcitabine has shown promising results in some phase I and
II trials as a radiosensitizing agent.4-6Gemcitabine is activated
intracellulary by deoxycytidine kinase and is converted into
two active metabolites gemcitabine diphosphate and tri-
phosphate which target DNA and RNA. It is considered to be
an attractive compound to combine with ionizing radiation
for several reasons: 1) It may inhibit repair of the DNA
damage caused by radiation leading to increased cell death; 2)
It may induce cell redistribution causing cells to accumulate
in more radiosensitive phase of cell cycle; 3) Increased the
radiosensitvity of hypoxic cells due to tumor shrinkage. Mc
Cormach et al.7 used gemcitabine with radiation in patients
with locally advanced cervical cancer and concluded that
gemcitabine is more potent radiosensitier than cisplatin while
Srivastava et al.8 found that cisplatin appeared to be better
than gemcitabine when used as radiosensitizer.
This study was undertaken to evaluate the efficacy and safety
of a concurrent regimen of gemcitabine / cisplatin and radi-
otherapy in women with stage IIB-IIIB cervical carcinoma.
Methods and Materials
Women with untreated invasive squamous cell carcinoma of
the cervix of FIGO stage IIB-IIIB were enrolled in this study
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from April 2010 to December 2013. All cases were confirmed
histologically. Each patient was required to undergo a com-
plete physical examination, pelvic examination, chest radi-
ography, intravenous pylography (IVP) and abdomino-pelvic
magnetic resonance imaging (MRI). Sigmoidoscopy and cys-
toscopy were performed if needed. All patients were to have
ECOG performance status score of 0 – 2, adequate bone
marrow reserve (ANC >1500 /mm3, platelet count >100.000 /
mm3 and Hb ≥10 g /dL), renal function (serum creatinine ≤1.5
mg /dl), liver function (bilirubin <2 times upper limit of
normal (ULN) and SGOT<3 times ULN). Patients with dis-
eases outside the pelvis or with para-aortic lymph node were
excluded from the study.
Radiotherapy
External beam radiotherapy (EBRT), 50 Gy/25 fractions was
delivered using 6-10 MV photon beam through 4 field box
technique. Typical field borders were; upper border was at
L4-5 inter space; lower border at lower most part of obturator
foramen and was modified according to vaginal extent of the
disease; anterior border was at the anterior symphysis pubis
and the posterior border at S2-S3 junction. Additional 600
cGy may be boosted to the invaded parametrium if was still
felt thickened on evaluation by pelvic examination.
For intracavitary radiotherapy (ICRT), patients were referred
to other centers after completion of EBRT. All patients re-
ceived single application of ICRT to deliver 20 Gy at point A.
Chemotherapy
Gemcitabine at a dose of 125 mg /m2 was given by i.v infusion
over 30 minutes in 300 ml normal saline immediately after
cisplatin 20 mg /m2 weekly for 5 weeks during EBRT, begin-
ning on first day of radiation. Cisplatin infusion was admin-
istered with adequate pre and post hydration; started 12h
before infusion. Prophylactic antiemetic (dexamethasone,
ranitidine and ondansetron) were given before cisplatin.
Chemotherapy and radiotherapy toxicity were assessed ac-
cording to Common Terminology Criteria for Adverse Events
V3 9 and RTOG classification 10 respectively.
When hematological toxicity was≥ grade 3, chemotherapy
and radiotherapy were withheld. For grade 2 hematological
toxicity only chemotherapy was withheld. When non he-
matological acute radiation morbidity was≥ grade 3, radiation
was interrupted.
Response to treatment was assessed according to response
evaluation criteria in solid tumors (RECIST) 11 after 3 weeks
of end of treatment.
Surgery was scheduled within 4-6 weeks after completion of
chemoradiotherapy for patients who became operable. His-
topathological response to treatment was defined as complete
regression (pCR) with no residual tumor cells and subtotal
regression (PSR) with < 10% viable tumor cells.
The end points of this study were response rate, tolerability,
overall survival (OAS) and progression free survival (PFS)
rates. The OAS was calculated from date of start treatment to
date of death or lost follow-up while PFS was calculated from
date of end of treatment to date of documented progression.
Patients were assessed every 3 months for first year then
every 6 months thereafter by clinical examination and ab-
domino pelvic MRI.
Statistical analysis: SPSS version15.0 (Chicago, IL, USA) was
used. Data expressed as Number and percentile. OAS and PFS
assessed by using Kaplan-Meier.
Results
A total of 45 patients were treated on protocol. Pre-treatment
clinical characteristics are summarized in Table 1. Median age
was 44 years. About 49% of patients had ECOGPS of 0. Most
patients had stage IIB (60%). Moderately differentiated
squamous cell carcinoma was found in 49% while ulcerative
pathology was reported in 64.5%.
































TABLE 2: Acute toxicities.
Toxicity Grade
1 2 3 4
N % N % N % N %
Neutropenia 4 8.9 6 13.3 2 4.4 0 0
Thrombocytopenia 6 13.3 7 15.6 1 2.2 0 0
Anemia 8 17.8 5 11.1 3 6.6 0 0
Nausea/vomiting 10 22.2 8 17.8 0 0 0 0
Dermatitis 5 11.1 3 6.6 0 0 0 0
Proctitis 7 15.6 5 11.1 0 0 0 0
Cystitis 6 13.3 8 17.8 0 0 0 0
Diarrhea 11 24.4 12 26.7 0 0 0 0
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TABLE 3: Response rate.
Response N %
Complete response (CR) 34 75.6
Partial response (PR) 8 17.8
Stable disease (SD) 2 4.4
Progressive disease (PD) 1 2.2
Pathological complete response (pCR) 28 62.2
All patients completed the treatment protocol with interrup-
tion in 3 patients only (6.6%) of about 3-6 days. Toxicity was
moderate. The incidence and severity of acute toxicities are
shown in Table 2. No grade 4 toxicity was recorded while
grade 3 was found in hematologic one only. Fortunately,
neither reported ototoxicity nor nephrotoxicity. Among
hematologic adverse events; anemia was the most common
(35.5%) followed by thrombocytopenia (31%). Diarrhea,
nausea and vomiting, and cystitis were found in respect to
order of frequency as following: 51%, 40%, 31%.
Overall clinical response rate was 93.4%; stable and progres-
sive diseases were 4.4% and 2.2% respectively. Operable
patients underwent type III radical hysterectomy with bilat-
eral pelvic lymphadenectomy and pathological complete
response was 62.2% (Table 3).
FIG. 1: Overall survival of all cases.
FIG. 2: Progression free survival.
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During follow-up period, two patients died of unrelated
causes of diseases; so survival rates were assessed in 43 pa-
tients. Figure 1 and Figure 2 showed 2-year overall survival
(OAS) and progression –free survival (PFS) rates (90.5% and
81%) respectively. After median follow-up of 20 months;
median survival time was 30 months while that of PFS was 26
months.
Discussion
Treatment of carcinoma of the cervix has evolved immensely
over the last decade. For locally advanced carcinoma of the
cervix, overall prognosis has always been somber until the
shift in the treatment paradigm came with concurrent
chemoradiotherapy protocol. The most standard approach is
the use of concurrent cisplatin 40 mg/m2 weekly along with
radiation but locoregional failure range from 30% to 40%.12, 13
Gemcitabine is a cell cycle specific cytotoxic agent that has
shown antitumor activity against a variety of solid tumors e.g.
lung, pancreas, breast and bladder.
Hernandez et al. 14 have demonstrated the radiosensitizing
effect of gemcitabine against cervical cancer cell line. Overall
toxicity was acceptable and tolerable. No patients demon-
strated ototoxicity or nephrotoxicity in this study. However;
previous study using weekly cisplatin 40mg/m2 had reported
ototoxicity in 10% 15 while nephrotoxicity occurred in 42.9%
in a study using weekly combination of gemcitabine with this
standard dose of cisplatin.16
Among hematologic toxicity; anemia was the most common
(35.5%) followed by thrombocytopenia (31%) then neutro-
penia (26.6%) with grade 3 in 4.4% and no grade 4 that
comparable to finding by Umanzor et al.6 However; Zarba et
al.5 recorded grade 4 neutropenia in 4%. Anemia was found in
50% of patients treated with gemcitabine 125mg/m2 and
cisplatin 40mg/m2.4 In our study; diarrhea, nausea and vom-
iting were the most common non hematologic adverse events
(51% and 40% respectively) with no grade 3 nor 4 toxicity
while Khalil et al.17 reported grade 3 and 4 diarrhea in 36.6%
when used cisplatin 40mg/m2 concurrent with radiotherapy.
Grade 1 and 2 diarrhea was observed in 50% of patients
treated with gemcitabine 300mg/m2 4 and 2-year survival rate
of 63% while that in our study was 94% but their patients
were of stage IB2-IVA. Overall clinical response rate in our
study was 93.4%, 2-year OAS and PFS rates were 90.5% and
81% respectively. In a study conducted by Pattaranutaporn et
al.4 response rate was comparable to ours. Also, Zarba et al. 5
had comparable response rate but with higher toxicity may be
due to higher dose of cisplatin. Overall response rate was
higher than that using cisplatin only 40mg/m2 (79.6%).
Conclusion
Weekly combination of low- dose cisplatin and gemcitabine
given concurrently with pelvic radiotherapy in primary
treatment of locally advanced cervical cancer resulted in a
high response rate with a good compliance. Further explora-
tion is needed for the use of this approach prior to incorpo-
rating it into routine clinical care through phase III clinical
trial.
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